Cytokine signaling from the tumor microenvironment can allow leukemia cells to survive targeted imatinib therapy, in the first report of a non-autonomous resistance mechanism. Targeted cancer ...

Imatinib, a drug that targets the BCR-ABL tyrosine kinase, has proved remarkably effective in restoring normal blood formation in people with CML; nevertheless, most individuals in remission have ...